Summary Population with Down syndrome (DS) has lower areal BMD, in association with their smaller skeletal size. However, volumetric BMD and other indices of bone microarchitecture, such as trabecular bone score (TBS) and calcaneal ultrasound (QUS), were normal. Introduction Patients with DS have a number of risk factors that could predispose them to osteoporosis. Several studies reported that people with DS also have lower areal bone mineral density, but differences in the skeletal size could bias the analysis. Methods Seventy-five patients with DS and 76 controls without intellectual disability were recruited. Controls were matched for age and sex. Bone mineral density (BMD) was measure by Dual-energy X-ray Absorptiometry (DXA), and volumetric bone mineral density (vBMD) was calculated by published formulas. Body composition was also measured by DXA. Microarchitecture was measured by TBS and QUS. Serum 25-hidroxyvitamin D (25OHD), parathyroid hormone (PTH), aminoterminal propeptide of type collagen (P1NP), and C-terminal telopeptide of type I collagen (CTX) were also determined. Physical activity was assessed by the International Physical Activity Questionnaires (IPAQ-short form). To evaluate nutritional intake, we recorded three consecutive days of food.
Introduction
Down syndrome (DS) is the most common intellectual disability and the most frequent chromosomal abnormality among live births [1] [2] [3] . Patients with DS have a number of risk factors that theoretically could predispose them to osteoporosis, such as reduced muscle tone and physical activity, limited sun exposure (due to institutionalization, physical disabilities, or skin diseases [4] ), frequent comorbidities (thyroid disorders, hypogonadism, celiac disease, etc.,), and drug therapies (corticoid or antiepileptic) [5, 6] . On the other hand, individuals with DS have a typical phenotype, including a reduced height and smaller skeletal size. Several studies [7] [8] [9] reported that people with DS also have lower areal bone mineral density (BMD), but few of them have taken into account the morphological differences of bone, and particularly the differences in bone size. Since the areal BMD (aBMD) estimates from the DXA machines represent the bone mineral content (BMC) divided by the projected area, it does not fully account for bone volume. As a consequence, BMD is underestimated in individuals with shorter height, making the true volumetric BMD (vBMD) a better index of the skeletal status than areal BMD [10, 11] . In a previous study, we found that skeletal size differences were largely responsible for the apparent differences in aBMD between patients with DS and normal individuals. In the present study, we aimed to confirm those results in a larger group of individuals with DS, to provide the reference ranges of aBMD in this population and to analyze the nutritional, anthropometric, and lifestyle factors determining bone mass.
Materials and methods

Study population
We included 151 men and women (75 with DS and 76 controls) over 18 years of age. Patients with DS were recruited from our DS clinic at the University Hospital Marqués de Valdecilla and the Down Syndrome Foundation of Cantabria (Spain). A convenience control group was recruited among volunteer hospital matched for age and sex distribution. Informed consent was obtained from the volunteers and the patients or their tutors. Exclusion criteria were the refusal to participate in the study, pregnancy, previous osteoporosis treatment, or physical disability that does not allow the realization of the densitometry. All participants were studied in the same period (November-December) to avoid seasonal differences in vitamin D levels.
Clinical and risk factor assessment
Data were obtained with a standardized interview and physical exam by one of the authors (MGH). Items included were age, sex, height (cm), weight (kg), and body mass index (BMI kg/ m 2 ), risk factors for osteoporosis (physical activity, sun exposure, and calcium intake), comorbidities, and treatments (anticonvulsant, anticoagulants, corticoid, diuretics, psychotropic) in the last 3 months, and also a history of fractures. Physical activity was assessed by the International Physical Activity Questionnaires (IPAQ-short form). It can quantify days in the week and minutes in the day people practice vigorous, moderate, or low intensity exercise, and it allows an estimation of the metabolic rate (in MET-minute/week) (www.ipaq.ki.se). We elaborated a sun exposure questionnaire to estimate the amount of exposure, their preferences, sunscreen, and UV radiation use. To evaluate nutritional intake, we recorded three consecutive days of food; participants registered all kinds of food ingested and the amounts [12] . Using the software Dietsource 3.0 (Nestle, Gen, Sw), the amount of macronutrients, minerals, fatty acids, and vitamins ingested was estimated.
Biochemical measurements
Blood samples were obtained in a fasting state between 09:00 and 12:00 am. Routine chemistries were analyzed the same day. Other parameters were analyzed in serum aliquots stored at −80°C until the samples were processed. Serum total calcium and albumin measurements were determined by standard automated methods in an ADVIA 2400 Chemistry System (Siemens Medical Solutions Diagnostics, Los Angeles, CA USA). Serum concentrations of 25-hydroxyvitamin D (25-OHD), parathyroid hormone (PTH), aminoterminal propeptide of type collagen (P1NP), and Cterminal telopeptide of type I collagen (CTX) were determined by a chemiluminescent immunoassay specific in a iSYS (IDS-iSYS Multi-Discipline Automated Analyzer, Pouilly-en Auxois, France). The detection limit of serum 25-OHD was 5 ng/ml, its intra-assay coefficient of variation (CV) was <10, and its inter-assay CV was <15. The detection limit of PTH was 6 pg/ml, with a normal range of 10-45 pg/ml. Intra-assay and inter-assay CV were 2.6 and 5.8 %, respectively. The P1NP limit of detection was 0.14 ng/ml (normal range 21-78 ng/ml in men and 19-102 in women), with an intra-assay and inter-assay CV of 2.9 and 4.7 %, respectively. The intra-assay and inter-assay CV of β-CTX was 3.2 and 6.2 % (normal range: 0.115-0.748 in men; 0.112-0.738 premenopausal woman and 0.142-1.351 ng/ml postmenopausal women). Testosterone and estradiol were determined by an automated competitive immunoassay in an ADVIA Centaur (Siemens Medical Solutions Diagnostics). Intra-assay and inter-assay CVof testosterone were 6.2 and 4.4 %, respectively, and the normal range was 2.41-8.27 ng/ml in men and 0.14-0.76 ng/ml in women. Regarding estradiol, the normal range was <50 pg/ml in men and in women it varies according to follicular phase; intra-assay CV was 7.4 % and inter-assay was 8.1 %.
Bone mass and body composition measurements BMC and aBMD were measured by DXA (Hologic QDR 4500, Waltham, MA) at the lumbar spine in L1-L4 (LS), femoral neck (FN), and total hip (TH) regions. In vivo precision was 0.51 % in LS, 0.47 % in FN, and 0.42 % in TH. Results were expressed as grams per square centimeter and Z-score (defined as the number of SDs below the mean value for women of the same age). Z-score was calculated according to the NHANES III reference database for femur measurements [13] . Quality control was performed following the usual standards. Due to the influence of bone size, we calculated vBMD at LS and FN using known formulas previously published [14, 15] . Body composition was also analyzed by DXA to assess fat mass and lean mass (both in grams and percentage) at the subtotal corporal (not including the head in the analysis). The trabecular bone score (TBS) was analyzed by the software v2.1. Quantitative ultrasound heel (QUS) measurements were performed in the right calcaneus using a Sahara sonometer (Hologic, Walthman, MA). This equipment measures the broadband ultrasound attenuation (BUA in decibel per megahertz) and the speed of sound (SOS in meters per second). BIn vitro^precision was 0.04 % for SOS, 5.1 % for BUA, and 0.32 % for BMD. BIn vivop recision was 0.56 % for SOS and 10.1 % for BUA. This device also combines the values of BUA and SOS to yield a parameter known as the Bquantitative ultrasound index( QUI), based on the following linear equation: QUI = 0.41 × (BUA + SOS) − 571.
Data analysis
The results were expressed as mean ± SD for quantitative variables and percentages for qualitative variables. For the comparison of groups, quantitative variables were analyzed by Student's test if the variables have normal distribution or Mann-Whitney test if the parameters did not have a normal distribution. The Chi-squared or Fisher's exact tests were used to identify differences in categorical variables between groups. A univariate linear regression analysis was carried out with either aBMD or vBMD as the dependent variables. Later, multivariate regression analyses were done using as predictors the factors that appeared as significant in the univariate analysis. A value of p < 0.05 was considered statistically significant.
Results
Demographic and clinical data
Mean age was 33 ± 10 years in DS and 33 ± 10 years in the controls, with a 52 % of males in both groups. People with DS had lower weight (60.4 ± 11.0 vs. 69.5 ± 13.4 kg; p = 1.0 × 10 −5 ) and height (151 ± 11 vs. 169 ± 9 cm; p = 1.0 × 10
) than the controls, but the BMI was higher (26.5 ± 4.4 vs. 24.1 ± 3.5 kg/m 2 ; p = 0.003). The characteristics are shown in Table 1 . When we assessed total physical activity, people with DS exercised for a similar amount of time (in days per week and minutes per day), but the intensity (measured as MET-minute per week) was lower than that of the controls. In fact, the amount of moderate and light exercise was similar in both groups. DS participants have more frequent sun exposure in days per week, but they tried to avoid direct exposure and used sun cream more frequently.
Regarding diet, macronutrient intake was similar in DS and the control group, except lipid intake, which was higher in the DS group. In general, people with DS have a higher intake of some vitamins (such as B1, B2, B6, B12, C, or A), but a similar intake of vitamin D. The intake of calcium, magnesium, and phosphorus was also similar in both groups. Regarding minerals, we only found differences in potassium and copper intake. The intake of Omega-3 fatty acids, like EPA or DHA, was higher in the DS group ( Table 1) .
As expected, patients with DS had more comorbidities than the general population. We found higher prevalence of hypothyroidism (37 vs. 0 %; p < 0.001), congenital heart disease (21 vs. 7 %; p = 0.009), epilepsy (7 vs. 0 %; p = 0.028), cataracts (12 vs. 1 %; p = 0.008), and skin disorders (12 vs. 0 %; p = 0.001). Accordingly, they took more frequently anticonvulsants (7 vs. 0 %; p = 0.028) and psychotropic drugs (22 vs. 4 %; p = 0.001). The prevalence of other diseases such as hypertension, diabetes mellitus, dementia, cancer (including solid organ tumors and leukemia), or celiac disease did not show statistically significant differences, but the absolute frequencies were low. The prevalence of fractures was similar, 11 % in the DS group and 12 % in the control group (p = 0.35), and most of these occur in the long bones (9 vs. 14 %; p = 0.23).
Bone mass, TBS, and QUS measurements
Absolute values of aBMD and the corresponding Z-scores were lower in individuals with DS with respect to the control group in all localizations. In LS, it was −1.40 ± 1.23 in DS and −0.50 ± 1.08 in the controls (p < 0.001), in FN it was −0.80 ± 0.94 in DS and −0.14 ± 0.85 in the controls (p < 0.001), and in TH −1.06 ± 0.76 in DS and −0.15 ± 0.89 in the controls (p < 0.001). However, there were no differences in the estimated vBMD in the two groups ( Table 2) . TBS was also similar in DS and the control groups (1456 ± 84 in DS vs. Those differences persisted after adjustment by anthropometric variables, such as height, weight, and the projected area of bone of lower extremities.
Body composition
Individuals with DS have less lean mass than the controls, both in absolute values and as percentage of body weight. Regarding the fat mass, the absolute values were similar in both groups, nevertheless, but the relative proportion of the body weight accounted for fat was higher in the DS group (Table 3) .
Bone and mineral metabolism
No differences were found in serum albumin-corrected calcium (9.0 ± 0.4 in DS vs. 9.1 ± 0.3 mg/dl in controls, p = 0.14).
Serum 25OHD levels were similar in both groups (22.6 ± 7.9 ng/ml in DS and 24.8 ± 9.5 ng/ml in controls; p = 0.14); also PTH levels were similar (24.3 ± 10.3 and 26.1 ± 13.7 pg/ml, respectively; p = 0.61). The prevalence of hypovitaminosis D (25OHD <20 ng/ml) was 39 % in DS and 35 % in controls (p = 0.39). Regarding bone turnover levels, β-CTX levels were similar in both groups, but P1NP and alkaline phosphatase levels were higher in people with DS. Serum testosterone levels were lower in males with DS than those in controls, whereas no differences existed in serum estradiol (Table 4) .
Factors associated with volumetric BMD
Some variables showed a relationship with vBMD in LS and FN in univariate regression analysis. The association was negative for age, height, protein intake, and testosterone levels and positive with the female sex and the percentage of fat mass (Table 5 ). In the multivariate analysis, only female sex remained positively associated with vBMD in LS (β-coefficient 0.417, p = 0.042), whereas age and the fat mass (as percentage of body weight) were associated with vBMD in FN (β-coefficient −0.343, p = 0.001 with age and β-coefficient 0.298, p = 0.012 with fat mass).
Reference values in DS population
Since the volumetric values are not usually provided in the DXA output, we built reference charts for aBMD in the DS population as a tool for the everyday care of these patients. Therefore, we plotted BMD against age in males and females with DS and also compared the distribution with the standard reference values for the normal population (Hologic reference in the lumbar spine and NHANES in the hip). As shown in Fig. 1 , BMD values in the DS group were lower than those in the general population, but the course over lifetime was similar in both groups.
Discussion
In this study, we confirmed that people with DS have lower aBMD (g/cm 2 ) than the general population. The average differences were 10 % in LS, 9 % in FN, and 12 % in TH. These results are similar to other studies [7] [8] [9] [10] [11] . Several factors might explain these differences between DS and the general population. Patients with DS have an accelerated aging process, but lower BMDs have also been demonstrated in the DS population at an early age [16] , thus suggesting the involvement of other factors besides aging. The DS population has growth retardation and a limited growth span, resulting in shorter height 25OHD 25-hidroxyvitamin D, PTH parathyroid hormone, P1NP procollagen type 1 N propeptide, β-CTX Cterminal telopeptide of type I collagen [7] [8] [9] [10] [11] (www.ipaq.ki.se). Accordingly, they have smaller bones. This fact is very important because it is known that bone size affects BMD measurement by DXA. BMD is calculated as the ratio between bone mineral content and bone area, but it does not take into account bone depth. Therefore, smaller bones tend to have lower areal BMD (aBMD) than bigger bones. This is the reason why we determined vBMD in addition to aBMD. Indeed, we confirmed our previous results, showing that bone size is the major factor explaining the reduced aBMD in the DS population, which was reflected by the fact that vBMD was similar in both groups. In line with this concept, the bone quality, measured by QUS and TBS, procedures that are less influenced by bone size were not lower in patients than those in controls. In fact, although TBS score was slightly correlated with the projected vertebral area (r = 0.24; p = 0.008), no between-group differences were found in either the unadjusted or the adjusted analysis. Unexpectedly, calcaneal ultrasound measurements were slightly better in patients with DS than those in controls, in the unadjusted analysis, as well as after adjustment by sex, age, weight, height, and the bone-projected area. Thus, although bone size may introduce some small bias in US estimates [17] , the anthropometric differences between patients and controls do not appear to influence those results. However, we cannot exclude completely an influence of subtle differences in the geometry of the calcaneus or in the subcutaneous tissues of the feet [18] . Although further studies are needed to fully explain these QUS data, our results show that most people with DS have Bhealthy bones.^Although we are not aware of other studies measuring TBS/QUS in the DS patients, it will be interesting to know if such a good bone quality is found in DS patients from other regions, as well as in patients of a more advanced age.
The increased levels of PINP in patients with DS, in comparison with controls, were an unexpected finding. They were observed in the absence of differences in bone resorption markers and somewhat lower levels of sex hormones. These results are contradictory with a previous small study, including 30 patients with DS and eight controls from the USA, in which suggestion for Blow-turnover^was reported in DS [19] . Apart from sample size differences, other factors, related to the ethnic background, lifestyle habits, and anthropometric characteristics (for example, the much higher BMI in the American study) may help to explain the different results. 970 Osteoporos Int (2017) 28:965-972
) evolution in males (left) and females (right). The DS population is represented as a continuous line (mean) and discontinuous (±2 SD) line, and the general population is represented as a thin line (mean) and a gray zone (±2 SD). LS BMD lumbar spine bone mineral density, FN BMD femoral neck bone mineral density, and TH BMD total hip bone mineral density Although we do not have a clear explanation for the finding of higher bone formation markers without concomitant increase in bone resorption markers, it is in line with the overall conclusion that our patients with DS were healthy regarding bone mass.
With respect to lifestyle, we found no differences between DS and controls regarding light exercise, but patients were less engaged in activities requiring vigorous exercise. Other studies obtained similar results [20, 21] . Many studies have shown the beneficial effect of physical activity on the skeleton, particularly during the growth period [22, 23] . Although we did not find significant correlations between physical activity and skeletal parameters (probably due, at least in part, to the sample size and the common involvement of our patients in social and exercise activities), daily physical activity and sport programs should be particularly encouraged in this population.
Regarding the dietary habits, in general, people with DS had a healthy diet. Similarly, to other reports [24, 25] , calorie, protein, calcium, and carbohydrate intakes were similar in both groups. The DS population ingested fewer lipids than the control group; nevertheless, they ingested more DHA and EPA. Regarding the body composition analysis, it can be observed that people with DS have less lean mass and higher percentages of body fat than controls. People with DS have several factors that, in theory, could lead to lower 25OHD levels, but we found no difference in 25OHD levels nor in the prevalence of hypovitaminosis D, defined as (25OHD <20 ng/ml (39 %), which was similar to those of controls and lower than that described in others studies that reported prevalence of hypovitaminosis D between 74 and 93 % [26, 27] .
Our study also allowed to build some charts showing the evolution of aBMD in relation to age in people with DS. We feel that these graphs can be very useful for clinicians caring for patients with DS. Our data show that standard DXAderived T-and Z-scores using the general population as reference clearly underestimate bone density in patients with DS. In the absence of data relating fracture risk with aBMD, vBMD, or QUS in this population, we would suggest clinicians to use the provided charts (or the estimated vBMD) and QUS when evaluating the skeletal status of patients with DS.
This study has several limitations. We estimated vBMD with formulas that model bones as perfect cubes and cylinders and is less accurate than other methods, such as quantitative CT. Nevertheless, the consistency of our results provides good support for the conclusions. Importantly, although we used common noninvasice techniques, such as TBS and QUS, to get some insight about bone Bquality,^we did not obtain direct measurements of bone microstructure and quality (such as t h o s e e s t i m a t e d f r o m q u a n t i t a t i v e m i c r o C T o r microindentation). Also, the control group was not a random sample of the population, but healthy volunteers. Therefore, they may be a sort of Bsupercontrols,^which might introduce some bias. However, if such bias actually existed, it would further reinforce the conclusion that bone tissue is normal in DS. The moderate sample size also limited the precision of estimates, particularly among older individuals. This resulted in wide reference ranges in the aBMD charts in those with advanced age. Likewise, the sample size likely limited the statistical power to identify all the nutritional and lifestyle factors associated with skeletal parameters.
In conclusion, in this cohort of patients with DS with healthy lifestyles, areal BMD was low, in association with their smaller skeletal size. However, volumetric BMD and other indices of bone microarchitecture, such as TBS and calcaneal ultrasound, were normal. These results emphasize that in the presence of adequate environmental factors, individuals with DS are able to develop their whole potential and attain a small but normal skeleton.
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